皓元医药: 上海皓元医药股份有限公司2025年半年度报告摘要

Core Viewpoint - Shanghai Haoyuan Pharmaceutical Co., Ltd. plans to distribute a cash dividend of 0.80 yuan per 10 shares, totaling approximately 16.97 million yuan, which represents 11.18% of the net profit attributable to shareholders for the first half of 2025 [1][2]. Financial Performance - Total assets increased by 6.13% to approximately 5.84 billion yuan compared to the end of the previous year [2]. - Operating revenue for the reporting period was approximately 1.31 billion yuan, reflecting a 24.20% increase from approximately 1.06 billion yuan in the same period last year [3]. - Total profit rose significantly by 130.95% to approximately 181.62 million yuan compared to approximately 78.64 million yuan in the previous year [3]. - Net profit attributable to shareholders, after deducting non-recurring gains and losses, was approximately 140.57 million yuan, up 111.40% from approximately 66.50 million yuan in the same period last year [3]. - Basic and diluted earnings per share were both 0.72 yuan, representing an increase of 118.18% from 0.33 yuan in the previous year [3]. Shareholder Information - As of the end of the reporting period, the total number of shareholders was 10,882 [3]. - The top ten shareholders included various entities, with the largest shareholder holding 3.96% of the shares [4].